Business
REGENXBIO Reports Second Quarter 2019 Financial and Operating Results and Additional Positive Interim Phase I/IIa Trial Update for RGX-314 for the Treatment of Wet AMD
ROCKVILLE, Md., Aug. 7, 2019 /PRNewswire/ -- Reports further positive interim update from RGX-314 Phase I/IIa trial for Wet AMD Well-tolerated at all doses
About this update from Regenxbio Inc.
[{"type":"text","content":"ROCKVILLE, Md., Aug. 7, 2019 /PRNewswire/ --\nReports further positive interim update from RGX-314 Phase I/IIa trial for Wet AMD Well-tolerated at all doses Dose-dependent protein expression levels observed across all five dose cohorts 50% of subjects treated in Cohort 3 remain free of anti-VEGF injections at 18 months Company plans to present interim data update from all five dose cohorts in October 2019 Remains on-track to initiate Phase IIb trial in late 2019Continues dosing in the RGX-501 Phase I/II trial for HoFH and the RGX-121 Phase I/II trial for MPS II Expanded pipeline using NAV® Vectors to deliver therapeutic antibodies for the treatment of hereditary angioedema and neurodegenerative diseases Launch of first FDA-approved gene therapy based on REGENXBIO's NAV Technology Platform, Novartis' Zolgensma® for the treatment of SMA $450 million in cash, cash equivalents and marketable securities as of June 30, 2019 Webcast and conference call scheduled for today at 4:30 p.m. ETREGENXBIO Inc. (Nasdaq: RGNX), a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy based on its proprietary NAV® Technology Platform, today announced financial results for the quarter ended June 30, 2019, and recent operational highlights.\n\"We are encouraged by the continued positive interim data from the Phase I/IIa RGX-314 trial and the potential of NAV gene therapy as a one-time treatment for wet AMD, and look forward to sharing six-month results from all five cohorts in the trial in October 2019,\" said Kenneth T. Mills, President and Chief Executive Officer of REGENXBIO. \"In our clinical trial for wet AMD, we have seen dose-dependent increases in protein expression levels across cohorts, and 50% of Cohort 3 subjects continued to be free of anti-VEGF injections at 18 months following a single administration of our gene therapy. These findings are particularly encouraging, given the severity of the disease and the high anti-VEGF injection treatment burden of these enrolled patients prior to administration of RGX-314. With feedback from the FDA provided at our recent Type B meeting, we also look forward to our anticipated start of the Phase IIb trial in late 2019.\"\nMr. Mills added: \"In addition to our excitement around RGX-314, the past quarter was highlighted by important milest...